verified99%+ Verified Purity
local_shippingFast EU Delivery (through resellers)
Myotrope
Homechevron_rightAll Peptideschevron_rightCagrilintide Injection Pen
Cagrilintide Injection Pen
verified_user

Safety data sheet

Standardized safety protocols and material specifications for professional use.

analytics

Certificate of Analysis

Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-cagrilintide-injection-pen-5mg

Official Product Data Sheet

Cagrilintide Injection Pen (5mg)

High >98% Purity

Vial Contents
5 mg Cagrilintide (3 mL pre-filled injection pen)
Includes
Ready-to-use multi-dose injection pen — no mixing required
Form
Pre-filled multi-dose pen
Purity
≥98%, third-party verified
Sequence
Amylin Analog
Molecular Formula
See chemical properties
Molecular Mass
4409 g/mol
CAS No.
1415456-99-3
Solubility
Concentration: ≈1.67 mg/mL | Per click: 1 unit ≈ 16.67 mcg (0.016 mg)
Storage
Refrigerate at 2–8 °C. Protect from light. Do not freeze.

Authorized Resellers

Available through our trusted partners

12
verifiedVerified

123peptide.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
DE
verifiedVerified

Depeptidenwinkel.com

Netherlands · Europe

local_shipping2-3 Business Days

Buy from Partneropen_in_new
View all authorized resellersshopping_cart
swipe_rightSwipe to see all tabs

Scientific Background

Cagrilintide is a long-acting amylin analog that activates amylin receptors to reduce appetite, slow gastric emptying, and promote satiety — complementing GLP-1 agonists through an entirely separate signaling pathway. Phase 3 CagriSema trial data demonstrates powerful synergistic weight loss when combined with Semaglutide, with 24% average weight reduction.

Intended Research Use

  • Amylin receptor activation and satiety signaling research
  • Gastric emptying rate and food intake studies
  • GLP-1 combination synergy research
  • Long-acting satiety peptide pharmacokinetics
  • Obesity and metabolic syndrome research

menu_bookScientific Publications

article

N Engl J Med (2025)

Cagrilintide and Semaglutide — REDEFINE 1 Trial

open_in_newhttps://pubmed.ncbi.nlm.nih.gov/39819825/

warning

FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.

Myotrope

Possible stacks with other peptides

Synergistic combinations for enhanced research outcomes

Cagrilintide's amylin pathway is complementary to GLP-1 agonists for additive satiety and weight loss.

Semaglutide 5mg

Semaglutide 5mg (5mg vial)

arrow_forward

myo-semaglutide-5mg

Amplified GLP-1 synergy — the CagriSema combination achieves 24% average weight reduction by targeting both amylin and GLP-1 pathways simultaneously.

Retatrutide 10mg

Retatrutide 10mg (10mg vial)

arrow_forward

myo-retatrutide-10mg

Triple-agonist power + amylin signaling for ultimate metabolic research breadth.

AOD-9604 5mg

AOD-9604 5mg (5mg vial)

arrow_forward

myo-hgh-fragment-aod-9604-5mg

Targeted fat breakdown in stubborn zones alongside Cagrilintide's appetite control.

schedule

Cycling Note: Typical protocol: 16–52 weeks with gradual 2-week titration steps. Monitor body weight and metabolic markers regularly.

Also Available

Cagrilintide 5mg
Vial

Cagrilintide

5mg

Cagrilintide 10mg
Vial

Cagrilintide

10mg

Cagrilintide Injection Pen 10mg
Pen

Cagrilintide Injection Pen

10mg